Trial Profile

A Phase I/II Study of the Combination of Venetoclax, Ponatinib and Corticosteroids in Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Lymphoid Blast Phase Chronic Myelogenous Leukemia

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ponatinib (Primary) ; Venetoclax (Primary) ; Corticosteroids; Dexamethasone; Dexamethasone; Rituximab
Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

08 May 2025 Status changed from completed to discontinued. (The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department )
28 Jun 2024 Status changed from active, no longer recruiting to completed.
19 Jul 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com